Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LIPE | Q05469 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.50 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CDK4 | P11802 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCND1 | P24385 | 1/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5630778 | 0.90 | HTR1A (0.56) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL9043854 | 0.85 | ALOX5 (0.51) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL339812 | 0.85 | MAPT (0.71) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL29510942 | 0.85 | ALDH1A1 (0.61) | MAPTMAPK1L3MBTL1ALDH1A1RECQL | |
| SCHEMBL238824 | 0.85 | ALDH1A1 (0.61) | MAPTMAPK1L3MBTL1ALDH1A1RECQL | |
| SCHEMBL8545383 | 0.85 | CYP4F2 (0.54) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL23582876 | 0.84 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL29847096 | 0.84 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| Water SCHEMBL7910704 | 0.84 | CYP4F2 (0.53) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| Water SCHEMBL7910705 | 0.84 | CYP4F2 (0.53) | HTR1AADRA1DADRA1AADRA1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-5273993-A | Antiarthritic agents; osteoporosis | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-12-28 | — | — | US | disclosed |
| US-5194446-A | Antiarthritic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-03-16 | — | — | US | disclosed |
| US-5025031-A | Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants | A. H. ROBINS CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HTR1A 4866/4885ADRA1D 4779/4885ADRA1A 4721/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HTR1A 4866/4885ADRA1D 4779/4885ADRA1A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.